October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
August 27, 2012 - N30 Pharma Converts from LLC to C-Corp

October 14, 2013 - Next generation F508del CFTR correctors using a YFP based high throughput screening assay
October 14, 2013 - Intestinal Current Measurement to Assess Modulation of F508del-CFTR Function
October 14, 2013 - A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity
March 21, 2013 - S-nitrosoglutathione Reductase Inhibitors Modulate F508-del CFTR Protein Levels and Chloride Secretion In Vitro
March 20, 2013 - Small Molecule Inhibitors of GSNOR Possess Anti-Inflammatory and Bronchodilatory Actions in Mouse Models of Inflammatory Lung Disease and Modulate CFTR Function in F508del-CFTR Mice

Contact Us

3532 British Circle, Ste 530
Boulder, CO 80531
7532-945-77500

January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement